Natco Pharma

  • Natco Pharma shares surge 5.3 pc after patent ruling March 5, 2013

    Mumbai: Shares in Natco Pharma Ltd surge 5.3 per cent after an Indian patent appeals board upheld on Monday a decision to allow the company to sell a generic version of Bayer AG's cancer drug Nexavar. "It would have positive earnings implication for Natco and opens up new avenues of compulsory...
  • Cancer drug made cheaper, patients to benefit March 13, 2012

    Mumbai: The Indian Patent Office has given the Hyderabad-based Natco Pharma Limited the go-ahead in the form of a compulsory license to legally make and sell a low-cost generic version of German company Bayer's anti-cancer drug, Nexavar. The Controller of Patents PH Kurian, in a 62-page ruling, observed that with Nexavar...
  • Industry split over nod to Natco to sell Bayer's drug March 13, 2012

    New Delhi: India's decision to allow Natco Pharma to sell Bayer's patented cancer drug Nexavar has divided the pharmaceutical industry with domestic firms welcoming it while multinationals said 'arbitrarily' using of compulsory licenses will undermine innovation in the sector. Disappointed with the development, Bayer said it is evaluating options for its...
  • Rs 2.84-lakh cancer drug to cost Rs 8,880 March 13, 2012

    New Delhi: Bringing huge relief to cancer and kidney patients in India, the government on Monday allowed Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder and German multinational Bayer Corporation under Section 84 of the Indian...
  • Pharma companies line up to bag Tamiflu contract August 13, 2009

    New Delhi: As the H1N1 Influenza virus (swine flu) death toll rises, pharma companies are lining to bag the contracts for Tamiflu. Five pharma companies are in the race as the government looks to procure close to 20 million Tamilflu capsules over the next few weeks. The drug is the only...